Belsomra vs Trazodone: What to Do When One Fails

How Each Drug Actually Works

Suvorexant and trazodone do not share a mechanism. Understanding the difference tells you exactly which patients each drug fits and why a failure in one does not predict failure in the other.

Suvorexant: Turning Off the Wake Drive

Suvorexant blocks orexin-1 and orexin-2 receptors (OX1R and OX2R) in the lateral hypothalamus. Orexin peptides are the brain's primary arousal-promoting signals. By blocking them, suvorexant reduces the drive to stay awake rather than forcing sedation. The result is a gentler sleep onset and fewer nocturnal awakenings without the respiratory depression seen with benzodiazepines.

In the key Phase 3 program, Herring et al. (Lancet Neurology, 2014) enrolled 1,021 patients across two parallel 3-month trials. Suvorexant 20 mg and 40 mg significantly reduced subjective time to sleep onset and wake after sleep onset (WASO) versus placebo. At one month, the 40 mg dose cut polysomnographic WASO by approximately 28 minutes (P<0.001). Sleep efficiency improved across both doses, with the effect sustained at three months [1].

Trazodone: Sedation Through Receptor Blockade

Trazodone at antidepressant doses (150 to 400 mg) inhibits serotonin reuptake. At the lower doses used for insomnia (25 to 150 mg), the dominant action is antagonism at histamine H1 and serotonin 5-HT2A receptors, producing sedation and reduced sleep latency. It does not act on GABA-A receptors, orexin receptors, or melatonin receptors.

Mendelson (Journal of Clinical Psychiatry, 2005) reviewed the evidence base for trazodone in primary insomnia and concluded that "trazodone was more effective than placebo in improving sleep, but the evidence base is smaller and of shorter duration than that for established hypnotics" [2]. Polysomnographic data across the reviewed trials showed increased total sleep time and reduced sleep latency, with the most consistent benefit during the first two weeks of use.

Why the Mechanism Gap Matters for Failure Analysis

A patient who fails suvorexant because of persistent hyperarousal rooted in hypothalamic-pituitary-adrenal axis dysregulation may respond to trazodone's sedating antihistamine load. A patient who fails trazodone because of orthostatic hypotension or next-day sedation at doses needed for effect may do well on suvorexant's targeted orexin blockade. Mechanism mismatch is the most common reason one agent fails while the other succeeds.

Defining "Failure": Three Distinct Scenarios

Not all drug failures are the same. Before switching, a clinician needs to identify which failure mode applies. Each scenario has a different management path.

Scenario 1: Inadequate Efficacy at Adequate Dose

For suvorexant, inadequate efficacy means the patient still reports more than 30 minutes to fall asleep or more than 30 minutes of nocturnal waking after reaching the 20 mg dose. Some patients metabolized by CYP3A4 inducers (e.g., rifampin, carbamazepine) clear suvorexant too rapidly; checking for drug interactions is the first step before labeling the drug a failure.

For trazodone, inadequate efficacy after two weeks at 100 mg warrants a dose increase to 150 mg before switching. Patients with severe comorbid anxiety or pain-driven insomnia frequently need adjunctive treatment rather than a swap.

Scenario 2: Intolerable Side Effects

Suvorexant's most clinically significant side effect is next-morning somnolence, reported in roughly 7% of patients on 20 mg versus 3% on placebo in the Herring program [1]. Complex sleep behaviors, including sleep-driving and sleep-eating, carry an FDA black-box warning added in 2019 for all orexin antagonists [3]. Any such event is an absolute indication to stop suvorexant immediately rather than dose-reduce.

Trazodone's main tolerability issue at sleep doses is orthostatic hypotension, which may affect up to 5% of patients, particularly those over 65 or on antihypertensives. Priapism, though rare (estimated 1 in 6,000 male patients), is a urological emergency and an absolute contraindication to restarting the drug [4].

Scenario 3: Tolerance and Rebound

Suvorexant does not appear to cause clinically significant rebound insomnia on discontinuation, a finding confirmed in Herring's 2014 one-week discontinuation analysis, where subjective sleep parameters did not worsen below pre-treatment baseline [1]. Trazodone similarly carries low physical dependence risk, though a minority of patients report transient worsening of sleep for three to five nights after stopping doses above 100 mg.

If either drug loses efficacy after two to four weeks of initial response, consider non-pharmacological factors: alcohol use (disrupts sleep architecture), blue-light exposure, and variable wake times are the three most common saboteurs of maintained medication response.

Comparing Efficacy Profiles Head-to-Head

No published randomized controlled trial has directly compared suvorexant against trazodone in a single population with shared inclusion criteria. The comparison below draws from parallel trial data and pharmacological reasoning.

Sleep-Onset vs. Sleep-Maintenance Benefit

Trazodone's sedating histamine blockade accelerates sleep onset reliably. It has less strong data on maintaining sleep through the second half of the night, when adenosine pressure is lower and orexin signaling matters more. Suvorexant's WASO reduction data from Herring et al. Suggests a stronger effect on sleep maintenance than most comparators in the DORA class [1].

A patient whose primary complaint is difficulty falling asleep with normal maintenance may respond better to trazodone. A patient whose primary complaint is waking at 2 or 3 a.m. And being unable to return to sleep is a better candidate for suvorexant.

Effect on Sleep Architecture

Trazodone suppresses slow-wave sleep modestly and may increase Stage N2 sleep. Suvorexant increases REM sleep duration, a finding reproduced in polysomnographic substudies of the Phase 3 trials [1]. For patients with REM sleep behavior disorder or at high risk of REM-related phenomena, this is a relevant distinction. Increased REM is generally positive for mood and memory consolidation but warrants monitoring in REM behavior disorder patients.

Special Populations

Older adults (age 65 and older). The FDA-approved label for suvorexant recommends the same 10 mg starting dose in elderly patients. Trazodone's orthostatic hypotension risk is more pronounced in this group, and the American Geriatrics Society Beers Criteria lists trazodone as a medication that may increase fall and fracture risk in older adults [5].

Patients with comorbid depression. Trazodone at doses of 150 mg and above has meaningful antidepressant activity. A patient with insomnia driven by depression may benefit from a dose range that treats both conditions. Suvorexant has no antidepressant effect.

Patients with obstructive sleep apnea (OSA). Benzodiazepines and Z-drugs are relatively contraindicated in OSA because of respiratory depression. Suvorexant lacks direct respiratory depressant effects and has been studied in mild-to-moderate OSA patients without significant oxygen desaturation worsening [6]. Trazodone at low doses appears similarly safe in treated OSA, though data are limited.

When Belsomra Fails: Practical Next Steps

When suvorexant fails, the decision pathway has three branches.

Branch 1: Inadequate Response to Suvorexant

First, confirm the dose is adequate. Suvorexant is available in 5, 10, 15, and 20 mg tablets. The maximum recommended dose is 20 mg. Patients on moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil) should start at 5 mg; the effective dose in this group may be lower than expected. If the patient has not reached 20 mg, titrate up before declaring failure.

If 20 mg is already in use and efficacy is still poor, consider:

1. Adding cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians recommends as first-line treatment for chronic insomnia [7]. Medication augments CBT-I; it does not replace it.
2. Switching to trazodone 50 mg at bedtime, with a plan to titrate to 100 mg at two weeks if response is partial.
3. Considering low-dose doxepin (Silenor, 3 or 6 mg), another histamine antagonist with an FDA approval specifically for sleep maintenance insomnia.

Branch 2: Side-Effect-Driven Discontinuation of Suvorexant

Next-morning grogginess is dose-dependent. A step-down from 20 mg to 10 mg often resolves somnolence while preserving meaningful WASO reduction. If the patient cannot tolerate even 10 mg, transition to trazodone 25 to 50 mg. Trazodone's different mechanism means residual next-day sedation may or may not carry over; begin at the lowest dose and assess at two weeks.

Complex sleep behaviors require immediate discontinuation. Trazodone is a reasonable next agent because it does not act through mechanisms associated with complex sleep behaviors, though isolated case reports exist for most hypnotics.

Branch 3: Loss of Efficacy After Initial Response

Tolerance to suvorexant is not pharmacologically well characterized. If efficacy erodes after two months of stable response, a structured one-month drug holiday with intensive CBT-I is preferable to dose escalation above 20 mg (which is off-label and not supported by the trial data). After the drug holiday, restart at 10 mg to reassess the response threshold.

When Trazodone Fails: Practical Next Steps

Branch 1: Inadequate Response to Trazodone

Confirm the dose has reached at least 100 mg before attributing failure to the drug. Many primary care prescribers stop at 50 mg when the patient reports some but incomplete benefit. The therapeutic range for insomnia extends to 150 mg for most adults.

If 100 to 150 mg produces no meaningful benefit after three weeks, switching to suvorexant 10 mg is well supported. The mechanism transition (from histamine/5-HT2A antagonism to orexin blockade) targets a completely different pathway and offers a meaningful probability of response even in a trazodone non-responder.

Branch 2: Side-Effect-Driven Discontinuation of Trazodone

Orthostatic hypotension is dose-related and often manageable with evening dosing plus hydration, but in patients over 70 or on loop diuretics, it is frequently not. Priapism requires permanent discontinuation. Morning sedation at 100 mg or above is common; try a dose reduction to 50 mg first. If a 50 mg trial still produces unacceptable daytime sedation, suvorexant's cleaner pharmacokinetic profile (half-life 12 hours, substantially cleared before the next morning at standard doses) may be better tolerated.

Branch 3: Dependence Concerns or Comorbid Substance Use History

Trazodone carries no scheduled status and poses minimal misuse risk. Suvorexant is Schedule IV. For patients with a history of sedative-hypnotic misuse or active substance use disorder, trazodone is typically preferred. If trazodone fails in this population, a sleep specialist referral and intensive CBT-I are the appropriate next steps before introducing a scheduled substance.

The Switching Protocol: Step-by-Step

Moving between suvorexant and trazodone requires attention to overlap timing, dose selection, and monitoring windows.

Switching from Suvorexant to Trazodone

• Stop suvorexant. No taper is required given the low physical dependence profile.
• Start trazodone 50 mg the following bedtime.
• Assess at two weeks. If sleep latency improvement is partial, titrate to 100 mg.
• Assess at four weeks. If response remains inadequate at 100 mg, increase to 150 mg or revisit the diagnosis (rule out undiagnosed sleep apnea, restless legs syndrome, or psychiatric comorbidity).
• Do not co-administer suvorexant and trazodone simultaneously outside of specialist supervision; additive CNS depression is possible.

Switching from Trazodone to Suvorexant

• Stop trazodone. Doses above 100 mg may warrant a two-night step-down (e.g., 100 mg for two nights, then stop) to avoid transient rebound wakefulness, though this is not formally required.
• Start suvorexant 10 mg the following bedtime.
• If no response at two weeks, increase to 20 mg. The 20 mg dose is the evidence-supported target from the Herring phase-3 data [1].
• Monitor for next-morning sedation at the first follow-up call or visit, typically five to seven days after initiation.

Combination Use: Is It Ever Appropriate?

No FDA-approved labeling for either drug supports routine co-prescription for insomnia. Combining two CNS depressants increases next-morning sedation and fall risk, particularly in adults over 65. A small subset of patients with comorbid depression who need both the antidepressant dose of trazodone (150 to 300 mg) and additional sleep-maintenance coverage may use trazodone plus low-dose suvorexant (10 mg) under psychiatry or sleep-medicine supervision. This combination is off-label and requires explicit informed consent, careful monitoring of morning alertness, and a plan to reassess every 30 to 60 days.

Non-Pharmacological Foundations: CBT-I Cannot Be Skipped

Both suvorexant and trazodone work better when the patient is also working on sleep hygiene and behavioral interventions. The American College of Physicians' 2016 Clinical Practice Guideline (based on a systematic review of 58 RCTs) recommends CBT-I as the first-line treatment for chronic insomnia disorder in adults [7]. Medications are second-line additions, not substitutes.

Sleep restriction therapy, stimulus control, and relaxation training consistently produce durable improvements in sleep-onset latency and WASO that outlast medication effects. A patient who fails two pharmacological agents without CBT-I has not yet had an adequate trial of evidence-based insomnia treatment. The Society of Behavioral Sleep Medicine offers a directory of CBT-I providers for patients who need referral [8].

A Note on Costs and Access

Suvorexant (Belsomra) remains brand-only in the United States as of early 2025; a 30-day supply typically runs USD 350 to 450 without insurance. Generic suvorexant is expected following patent expiry, though the exact timeline is not yet confirmed. Trazodone is available generically and costs USD 10 to 25 for a 30-day supply at most pharmacies, making it substantially more accessible for uninsured or underinsured patients.

When cost is the driver of non-adherence to suvorexant, trazodone is a clinically reasonable, evidence-supported alternative rather than a second-best choice. Insurance prior authorization for suvorexant often requires a documented trial of two prior agents, which means many patients encounter trazodone on the way to a suvorexant prescription regardless of clinical preference.